Suppr超能文献

松弛素-2可能通过减少纤维化、瘢痕形成和炎症来抑制子宫内膜异位症。

Relaxin-2 May Suppress Endometriosis by Reducing Fibrosis, Scar Formation, and Inflammation.

作者信息

Yoshino Osamu, Ono Yosuke, Honda Masako, Hattori Kyoko, Sato Erina, Hiraoka Takehiro, Ito Masami, Kobayashi Mutsumi, Arai Kenta, Katayama Hidekazu, Tsuchida Hiroyoshi, Yamada-Nomoto Kaori, Iwahata Shunsuke, Fukushi Yoshiyuki, Wada Shinichiro, Iwase Haruko, Koga Kaori, Osuga Yutaka, Iwaoka Michio, Unno Nobuya

机构信息

Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa 252-0375, Japan.

Department of Obstetrics and Gynecology, Teine Keijinkai Hospital, Hokkaido 006-0811, Japan.

出版信息

Biomedicines. 2020 Oct 31;8(11):467. doi: 10.3390/biomedicines8110467.

Abstract

Relaxin (RLX)-2, produced by the corpus luteum and placenta, is known to be potentially effective in fibrotic diseases of the heart, lungs, kidneys, and bladder; however, its effectiveness in endometriosis has not yet been investigated. In the present study, we conducted a comprehensive study on the effect of RLX-2 on endometriosis. We checked the expressions of LGR-7, a primary receptor of RLX-2, in endometriomas using immunohistochemistry. Endometriotic stromal cells (ESCs) purified from surgical specimens were used in in vitro experiments. The effects of RLX-2 on ESCs were evaluated by quantitative-PCR, ELISA, and Western blotting. Gel contraction assay was used to assess the contraction suppressive effect of RLX-2. The effect of RLX-2 was also examined in the endometriosis mouse model. LGR-7 was expressed in endometriotic lesions. In ESCs, RLX-2 increased the production of cAMP and suppressed the secretion of interleukin-8, an inflammatory cytokine, by 15% and mRNA expression of fibrosis-related molecules, plasminogen activator inhibitor-1 (PAI-1), and collagen-I by approximately 50% ( < 0.05). In the gel contraction assay, RLX-2 significantly suppressed the contraction of ESCs, which was cancelled by removing RLX-2 from the medium or by adding H89, a Protein Kinase A (PKA) inhibitor. In ESCs stimulated with RLX-2, p38 MAPK phosphorylation was significantly suppressed. In the endometriosis mouse model, administration of RLX-2 significantly decreased the area of the endometriotic-like lesion with decreasing fibrotic component compared to non-treated control ( = 0.01). RLX-2 may contribute to the control of endometriotic lesion by suppressing fibrosis, scar formation, and inflammation.

摘要

松弛素(RLX)-2由黄体和胎盘产生,已知其在心脏、肺、肾脏和膀胱的纤维化疾病中可能有效;然而,其在子宫内膜异位症中的有效性尚未得到研究。在本研究中,我们对RLX-2对子宫内膜异位症的影响进行了全面研究。我们使用免疫组织化学检查了RLX-2的主要受体LGR-7在子宫内膜瘤中的表达。从手术标本中纯化的子宫内膜异位症基质细胞(ESC)用于体外实验。通过定量PCR、酶联免疫吸附测定(ELISA)和蛋白质免疫印迹法评估RLX-2对ESC的影响。凝胶收缩试验用于评估RLX-2的收缩抑制作用。还在子宫内膜异位症小鼠模型中研究了RLX-2的作用。LGR-7在子宫内膜异位症病变中表达。在ESC中,RLX-2增加了环磷酸腺苷(cAMP)的产生,并使炎症细胞因子白细胞介素-8的分泌减少了15%,使纤维化相关分子纤溶酶原激活物抑制剂-1(PAI-1)和I型胶原蛋白的信使核糖核酸(mRNA)表达减少了约50%(P<0.05)。在凝胶收缩试验中,RLX-2显著抑制了ESC的收缩,通过从培养基中去除RLX-2或添加蛋白激酶A(PKA)抑制剂H89可消除这种抑制作用。在用RLX-2刺激的ESC中,p38丝裂原活化蛋白激酶(MAPK)的磷酸化显著受到抑制。在子宫内膜异位症小鼠模型中,与未治疗的对照组相比,给予RLX-2显著减小了子宫内膜样病变的面积,纤维化成分减少(P=0.01)。RLX-2可能通过抑制纤维化、瘢痕形成和炎症来控制子宫内膜异位症病变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1789/7693148/f73ac33cb8db/biomedicines-08-00467-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验